ImmunityBio licenses oral vaccine tech from IosBio

By The Science Advisory Board staff writers

January 12, 2021 -- ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.

OraPro is a patented oral delivery vaccine platform which enables the oral administration of thermally stable viral vector vaccines. The vectors are engineered to withstand temperatures of up to 50° C, allowing them to pass through the stomach without losing efficacy and providing long-term product stability at ambient temperatures. Oral administration of vaccines stimulates mucosal-associated lymphoid tissue to generate mucosal, systemic, and T-cell immune responses.

The hAd5 COVID-19 vaccine candidate has shown promising results in preclinical studies and is working with the U.S. Food and Drug Administration to initiate a phase I prime/boost clinical trial. So far, 20 participants have already been dosed with both low and high doses of the vaccine in a phase I trial with no serious adverse events.

Under the agreement, IsoBio has granted ImmunityBio exclusive rights to utilize the platform for ImmunityBio's COVID-19 vaccine. IsoBio will be eligible to receive royalties on net worldwide sales of the approved oral vaccine.

ImmunityBio uses Microsoft software to visualize SARS-CoV-2 spike protein
ImmunityBio has released results from a molecular dynamics simulation, conducted in collaboration with Microsoft, that provided a visualization of the...
ImmunityBio, NantKWest to merge
ImmunityBio and NantKWest have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a new immunotherapy and...
ImmunityBio COVID-19 oral vaccine effective in nonhuman primates
ImmunityBio's COVID-19 vaccine candidate has been shown to protect nasal and lung airways of nonhuman primates against SARS-CoV-2 in preclinical studies.
ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma...
ImmunityBio COVID-19 vaccine shows positive clinical results
ImmunityBio has demonstrated that antigens from its bivalent adenovirus-based vaccine candidate are recognized by SARS-CoV-2 reactive human T cells in...

Copyright © 2021 scienceboard.net


Conferences
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter